These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 9167749

  • 1. Phase I dose intensification study of 2-weekly epirubicin with GM-CSF in advanced cancer.
    Michael M, Toner GC, Olver IN, Fenessy A, Bishop JF.
    Am J Clin Oncol; 1997 Jun; 20(3):259-62. PubMed ID: 9167749
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Kornek G, Raderer M, Schenk T, Pidlich J, Schulz F, Globits S, Tetzner C, Scheithauer W.
    Cancer; 1995 Oct 15; 76(8):1356-62. PubMed ID: 8620409
    [Abstract] [Full Text] [Related]

  • 3. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
    Lalisang RI, Wils JA, Nortier HW, Burghouts JT, Hupperets PS, Erdkamp FL, Schouten HC, Blijham GH.
    J Clin Oncol; 1997 Apr 15; 15(4):1367-76. PubMed ID: 9193328
    [Abstract] [Full Text] [Related]

  • 4. Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Scheithauer W, Kornek G, Raderer M, Koperna-Mach K, Müller C, Karner J, Kastner J, Tetzner C.
    J Cancer Res Clin Oncol; 1995 Apr 15; 121 Suppl 3():R7-10. PubMed ID: 8698741
    [Abstract] [Full Text] [Related]

  • 5. Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hematologic toxicity induced by high-dose chemotherapy in patients with metastatic breast cancer.
    Hansen F, Stenbygaard L, Skovsgaard T.
    Acta Oncol; 1995 Apr 15; 34(7):919-24. PubMed ID: 7492381
    [Abstract] [Full Text] [Related]

  • 6. A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer.
    Weiss GR, Shaffer DW, DeMoor C, Rinaldi DA, Rodriguez GI, Eckardt JR, Stephens C, Von Hoff DD.
    Anticancer Drugs; 1996 Jun 15; 7(4):402-9. PubMed ID: 8826608
    [Abstract] [Full Text] [Related]

  • 7. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF, Michelotti A, Baldini E, Salvadori B, Gennari A, Da Prato M, Tibaldi C, Salzano E, Gentile A.
    Semin Oncol; 1996 Oct 15; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [Abstract] [Full Text] [Related]

  • 8. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
    Conte PF, Michelotti A, Baldini E, Tibaldi C, DaPrato M, Salvadori B, Giannessi PG, Gentile A, Biadi O, Mariani M.
    Semin Oncol; 1996 Feb 15; 23(1 Suppl 1):28-32. PubMed ID: 8629033
    [Abstract] [Full Text] [Related]

  • 9. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
    Paccagnella A, Favaretto A, Riccardi A, Danova M, Ghiotto C, Giordano M, Pappagallo G, Comis S, Panozzo M, Chieco-Bianchi L.
    Cancer; 1993 Aug 01; 72(3):697-706. PubMed ID: 8392903
    [Abstract] [Full Text] [Related]

  • 10. A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor.
    Philip PA, Rea D, Mitchell K, Carmichael J, Harris AL, Talbot DC.
    Clin Oncol (R Coll Radiol); 1999 Aug 01; 11(2):84-9. PubMed ID: 10378632
    [Abstract] [Full Text] [Related]

  • 11. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G, Spielmann M, Dieras V, Kayitalire L, Pouillart P, Guastalla JP, Soler-Michel P, Graffand N, Garet F, Dumortier A, Pellae-Cosset B, Chazard M.
    Semin Oncol; 1996 Feb 01; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM, Ratain MJ, Van Echo DA, Rosner G, Egorin MJ, Budman DR, Vogelzang NJ, Norton L, Schilsky RL.
    J Natl Cancer Inst; 1993 Aug 18; 85(16):1319-26. PubMed ID: 8340944
    [Abstract] [Full Text] [Related]

  • 13. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G, D'Aiuto G, Comella P, Apicella A, Thomas R, Capasso I, Di Bonito M, Cartenì G, Biglietto M, De Lucia L, Maiorino L, Piccolo S, Bianchi U, D'Aniello R, Lapenta L, Comella G.
    Breast Cancer Res Treat; 1999 Aug 18; 56(3):239-52. PubMed ID: 10573115
    [Abstract] [Full Text] [Related]

  • 14. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Murphy RF, Hamilton JM, Balis F, Steinberg S, Arbuck SG, Setser A, Jordan E, Chen A.
    J Clin Oncol; 1994 Mar 18; 12(3):560-8. PubMed ID: 8120554
    [Abstract] [Full Text] [Related]

  • 15. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL, Palackdharry CS, Padavic K, Haas N, Kilpatrick D, Langer C, Comis R.
    J Clin Oncol; 1994 Jun 18; 12(6):1251-8. PubMed ID: 8201386
    [Abstract] [Full Text] [Related]

  • 16. Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer.
    Gridelli C, D'Aprile M, Palmeri S, Curcio C, Rossi A, Gebbia V, Veltri E, Pepe R, Pistillucci G, Bianco AR.
    Am J Clin Oncol; 1996 Dec 18; 19(6):589-91. PubMed ID: 8931678
    [Abstract] [Full Text] [Related]

  • 17. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.
    Aglietta M, Monzeglio C, Pasquino P, Carnino F, Stern AC, Gavosto F.
    Cancer; 1993 Nov 15; 72(10):2970-3. PubMed ID: 8221563
    [Abstract] [Full Text] [Related]

  • 18. Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
    Venturini M, Del Mastro L, Testore F, Danova M, Garrone O, Lanfranco C, Latini F, Sertoli MR, Lionetto R, Queirolo P, Ardizzoni A, Rosso R.
    Cancer Chemother Pharmacol; 1996 Nov 15; 38(6):487-94. PubMed ID: 8823488
    [Abstract] [Full Text] [Related]

  • 19. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G, Spielmann M, Dieras V, Tubiana-Hulin M, Bonneterre J, Pouillart P, Kayitalire L, Guastalla JP, Graffand N, Garet F, Dumortier A, Pellae-Cosset B.
    Semin Oncol; 1997 Feb 15; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [Abstract] [Full Text] [Related]

  • 20. Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
    O'Dwyer PJ, LaCreta FP, Schilder R, Nash S, McAleer C, Miller LL, Hudes GR, Ozols RF.
    J Clin Oncol; 1992 Aug 15; 10(8):1352-8. PubMed ID: 1634926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.